Consideration of the APA practice guideline for the treatment of patients with panic disorder: Strengths and limitations for behavior therapy

Behavior Therapy

Volumn 32, Issue 2, 2001, Pages 259-281

  Craske, Michelle G ^a   Zucker, Bonnie G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; SEROTONIN UPTAKE INHIBITOR;

BEHAVIOR THERAPY; CLINICAL PRACTICE; COGNITIVE THERAPY; COST MINIMIZATION ANALYSIS; HUMAN; MEDICAL SOCIETY; MENTAL HEALTH CARE; PANIC; PRACTICE GUIDELINE; REVIEW;

EID: 0034783595     PISSN: 00057894     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0005-7894(01)80005-8     Document Type: Article

References (107)

1. Practice guideline for psychiatric evaluation of adults
2. Practice guideline for the treatment of patients with panic disorder
3. Panic attacks and panic disorder in cross-cultural perspective
4. Enhancing agoraphobia treatment outcome by changing couple communication patterns
5. Behavioral treatment of panic disorder
6. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial
7. Advances in the psychosocial treatment of anxiety disorders: Implications for national health care
8. Couples treatment of agoraphobia
9. Couples treatment of agoraphobia: Initial outcome
10. Alprazolam and exposure for panic disorder with agoraphobia attribution of improvement to medication predicts subsequent relapse
11. A crossover study of focused cognitive therapy for panic disorder
12. Complex cognitive therapy treatment for personality disorder patients
13. The effect of fluvoxamine, cognitive therapy, and placebo on abnormal personality traits in 44 patients with panic disorder
14. Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder
15. Sources of relapse after extinction in pavlovian and instrumental learning
16. Diagnostic comorbidity in panic disorder: Effect on treatment outcome and course of comorbid diagnoses following treatment
17. Long-term outcome in cognitive behavioral treatment of panic disorder: Clinical predictors and alternative strategies for assessment
18. Couples treatment of agoraphobia: A two-year follow-up
19. Update on empirically validated therapies, II
20. Defining empirically supported therapies
21. Sex, sex-role stereotyping and agoraphobia
22. Alprazolam in the treatment of generalized anxiety and panic disorder
23. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder
24. A controlled study of cognitive behavior therapy with buspirone or placebo in panic disorder with agoraphobia
25. Gender effects and alcohol use in panic disorder and agoraphobia
26. Behavioral treatment of panic disorder: A two-year follow-up
27. Cognitive therapy for antisocial and borderline personality disorders: Single case study series
28. Reliability of DSM-III-R anxiety disorder categories: Using the Anxiety Disorders Interview Schedule-Revised (ADIS-R)
29. Personality disorders do not influence the results of cognitive behavior therapies for anxiety disorders
30. Cultural aspects of morbid fears in Qatari women
31. Long-term effects of behavioural treatment for panic disorder with agoraphobia
32. Psychosocial treatments for posttraumatic stress disorder: A critical review
33. It was the best of times, it was the worst of times
34. Cognitive-behavioral treatment of obsessive thoughts: A controlled study
35. African-American patients with panic disorder and agoraphobia
36. Characteristics of African-American and white patients with panic disorder and agoraphobia
37. Some problems associated with "validated" forms of psychotherapy
38. Some comments on empirically supported treatments
39. Self-treatment of agoraphobia by exposure
40. Panic, agoraphobia, and panic disorder with agoraphobia: Data from a multicenter anxiety disorders study
41. Toward a more clinically valid approach to therapy research
42. Self-help plus minimal therapist contact in the treatment of panic disorder: A replication and extension
43. The use of bibliotherapy in the treatment of panic: A preliminary investigation
44. A meta-analysis of treatment outcome for panic disorder
45. The economic burden of anxiety disorders in the 1990s
46. Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder
47. Ataques de nervios in Puerto Rico: Culture-bound syndrome or popular illness?
48. A cross-cultural perspective on anxiety disorders
49. Exposure in-vivo of agoraphobics: Contributions of diazepam, group exposure, and anxiety evocation
50. The influence of propranolol on the exposure in vivo of agoraphobics
51. Limitations of manualized psychotherapy for everyday clinical practice
52. Self-directed versus therapist-directed cognitive behavioral treatment for panic disorder
53. Cognitive behavioral group treatment for social phobia: Comparison with a credible placebo control
54. The relationship of marital adjustment to agoraphobia treatment outcome
55. Interpersonal problems among patients suffering from panic disorder with agoraphobia before and after treatment
56. Personality traits among panic disorder with agoraphobia patients before and after symptom-focused treatment
57. Asian Americans
58. Validated treatments: Multiple perspectives and issues - Introduction to the series
59. Patient-therapist interaction in the behavioral treatment of panic disorder with agoraphobia
60. Empirically supported psychological therapies
61. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the national comorbidity study
62. Cognitive-behavioral therapy of panic disorder with secondary major depression: A preliminary investigation
63. Effects of cognitive-behavioral treatment for panic disorder with agoraphobia on concurrent alcohol abuse
64. A comparison of bibliotherapy and group therapy in the treatment of panic disorder
65. Personality disorders and the outcome of cognitive-behavioural treatment of panic disorder with agoraphobia
66. Alprazolam and exposure alone and combined in panic disorder with agoraphobia: A controlled study in London and Toronto
67. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia
68. Comorbid panic disorder and major depression: Implications for cognitive-behavioral therapy
69. The impact of comorbid mood and personality disorders in the cognitive-behavioral treatment of panic disorder
70. Behavioral, cognitive, and pharmacological treatments of panic disorder with agoraphobia: Critique and synthesis
71. The role of self-directed in vivo exposure in combination with cognitive therapy, relaxation training, or therapist-assisted exposure in the treatment of panic disorder with agoraphobia
72. Anxiety disorders research with African Americans: Current status
73. Paroxetine in the treatment of panic disorder: A randomized, double-blind, placebo-controlled study
74. Sex differences in panic disorder with agoraphobia
75. Applied relaxation vs. progressive muscle relaxation in the treatment of panic disorder
76. Maintenance of remission following cognitive behavior therapy for panic disorder: Possible deleterious effects of concurrent medication treatment
77. Are results of randomized controlled trials useful to psychotherapists?
78. Impact of personality functioning on cognitive behavioral treatment of panic disorder: A preliminary report
79. Comparison of personality disorders in different anxiety disorder diagnoses: Panic, agoraphobia, generalized anxiety, and social phobia
80. Obsessive compulsive disorder
81. Hispanic Americans
82. Age at onset, precipitating events, sex distribution, and cooccurrence of anxiety disorders
83. Tailor-made versus standardized therapy of phobic patients
84. Effects of treatment duration and severity of depression on the effectiveness of cognitive-behavioral and psychodynamic-interpersonal psychotherapy
85. Fluvoxamine, placebo, and cognitive behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia
86. Treatment of anxiety disorders in the elderly: Issues and strategies
87. Anxiety in the elderly: Course and treatment
88. A survey of anxiety disorders clinics in Canadian hospitals
89. A randomized trial of cognitive therapy and imaginal exposure in the treatment of chronic posttraumatic stress disorder
90. An expanded Anxiety Sensitivity Index: Evidence for a hierarchic structure in a clinical sample
91. Combined pharmacological and psychological treatment of panic disorder: Current status and future directions
92. The effects of cognitive-behavior therapy for panic disorder on comorbid conditions
93. Social phobia: A comparison of behavior therapy and atenolol
94. Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia
95. Transporting an empirically supported treatment for panic disorder to a service clinic setting: A benchmarking strategy
96. Effects of concurrent diazepam treatment on the outcome of exposure therapy in agoraphobia
97. Cognitive-behavior therapy for panic disorder delivered by psychopharmacologically oriented clinicians
98. The relationship between therapist characteristics and outcome of in vivo exposure treatment for agoraphobia
99. The results of exposure-based treatment in agoraphobia
100. Manual-based treatments: The clinical application of research findings
101. Behavior therapy at century close
102. Treatment of major depression in the context of panic disorder
103. Schema-focused therapy for personality disorders
104. Hierarchical structure and general factor saturation of the anxiety sensitivity index: Evidence and implications
105. Stability of catastrophic cognitions in panic disorder